The 6-month persistence on SSRIs and associated economic burden

Ereshefsky, Larry; Saragoussi, Delphine; Despiegel, Nicolas; Hansen, Karina; François, Clément; Maman, Khaled

doi:10.3111/13696998.2010.511050

Cited by 26 publications

(30 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adherence reduces with time from initial prescription. In depression, adherence was reported to drop from 95.5% to 52.6% over a 1-month period 5. Low adherence increases risk of hospitalisations and premature mortality 6–8.…”

Section: Introductionmentioning

confidence: 99%

Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the New Medicine Service

et al. 2015

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the New Medicine Service

et al. 2015

View full text Add to dashboard Cite

“…7,11,12,13,14 Common causes for relapse and recurrence in long-term MDD treatment include side effects and lack of adherence to treatment. 15 One study 16 reported the rate of persistence to treatment with an SSRI decreased from 95% at 1 month to 20% at 6 months. The importance of selecting appropriate and tolerable treatment strategies including adjunctive therapy early in the course of treatment may help to increase the likelihood of acute remission and long-term recovery.…”

mentioning

confidence: 99%

Long-Term Efficacy, Safety, and Tolerability of <span style="font-variant:small-caps; "> l</span>-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors

Zajecka¹,

Fava²,

Shelton³

et al. 2016

J. Clin. Psychiatry

View full text Add to dashboard Cite

Objective: To evaluate remission and recovery, safety, and tolerability for up to 12 months of open-label adjunctive l-methylfolate calcium 15 mg.Method: Subjects in this analysis were adult outpatients (18-65 years) enrolled from 2 acute, double-blind, placebo-controlled trials comparing adjunctive l-methylfolate and placebo for DSM-IV major depressive disorder (MDD) with an inadequate response to monotherapy selective serotonin reuptake inhibitor (SSRI). Subjects who completed the acute trial were offered to enroll in a 12-month, open-label treatment phase with l-methylfolate and continued SSRI treatment, with scheduled visits for efficacy, safety, and tolerability every 12 weeks. Subjects were enrolled between September 2006 and February 2010. Efficacy outcomes included predefined criteria for response, remission, recovery, relapse, and recurrence. Subjects treated with adjunctive l-methylfolate 15 mg were included in the efficacy analysis. Results: Of 68 subjects who met criteria for the 12-month open-label phase, 38% (n = 26) achieved full recovery, and none experienced a recurrence of MDD. For subjects entering the open-label phase in remission (n = 11), 91% (n = 10) achieved full recovery with l-methylfolate 15 mg, and none experienced a relapse or recurrence. Among 57 subjects who entered the openlabel phase as nonremitted, 61% (n = 35) achieved remission. Of subjects who entered the open-label phase with a response without remission (n = 4), 50% (n = 2) had full recovery, and of subjects entering the open-label phase with no response (n = 53), 26% (n = 14) met recovery criteria. Conclusions: Adjunctive l-methylfolate 15 mg/d may be an early option in patients who fail to adequately respond to antidepressant monotherapy, with preliminary evidence demonstrating sustained remission and sustained recovery. Trial Registration: ClinicalTrials.gov identifier: NCT00321152 Clin Psychiatry 2016;77(5):654-660 dx.doi.org/10.4088/JCP.15m10181 J

show abstract

“…[18][19][20][21] Because depression and anxiety may not be validly measured in administrative databases, numerous epidemiologic and cost studies use therapy adherence or persistence rate as measures of disorder resolution. [22][23][24][25][26] To date, little is known about the clinical characteristics and the health care costs associated with the remission or persistence of depressive and anxiety symptoms in AD users in real-world settings, in the older adult population.…”

mentioning

confidence: 99%

The Costs Associated with Antidepressant Use in Depression and Anxiety in Community-Living Older Adults

et al. 2013

View full text Add to dashboard Cite

Objective: To determine the costs associated with antidepressant (AD) use by depression and anxiety status in a public-managed health care system. Methods:Data were obtained from a population-based health survey of 1869 older adults. Depression and anxiety were based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria and measured at 2 time points 1 year apart. AD and health service use and costs were identified from provincial administrative databases and included hospitalizations, physician fees, outpatient medications, and ambulatory visits. Patient costs considered were related to drug copayments, transportation, and time spent seeking medical care. Annual costs associated with AD use were studied as a function of mental health status at baseline and follow-up interviews (persistence, incidence, remission, or no illness). Generalized linear models with a gamma distribution were used to control for individual factors.

show abstract

The 6-month persistence on SSRIs and associated economic burden

Cited by 26 publications

References 33 publications

Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the New Medicine Service

Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the New Medicine Service

Long-Term Efficacy, Safety, and Tolerability of <span style="font-variant:small-caps; "> l</span>-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors

The Costs Associated with Antidepressant Use in Depression and Anxiety in Community-Living Older Adults

Contact Info

Product

Resources

About